Scholarlink

<p>Cancer vaccines have garnered significant attention in cancer immunotherapy because they trigger tumor-specific immune responses. However, their effectiveness is hindered by inefficient antigen and adjuvant delivery at the subcellular level, which is essential to stimulate a robust CD8<sup>+</sup> T cell response. This study presents PAR/OVA, a cancer nanovaccine developed by combining imiquimod (R837)-modified polyamidoamine dendrimers with the model protein antigen ovalbumin (OVA). Within the nanovaccine, R837 is an adjuvant for the Toll-like receptor 7 (TLR7) pathway and a structural component that facilitates OVA loading. In dendritic cells (DCs), the high cytoplasmic glutathione levels triggered the breakdown of PAR/OVA, releasing OVA and R837, which induced DC activation and antigen cross-presentation. Furthermore, PAR/OVA vaccination showed a protective effect and effectively inhibited B16-OVA tumor progression, indicating its potential in cancer immunotherapy. Combining this vaccine with an immune checkpoint blockade enhanced antitumor efficacy by improving the ability of cytotoxic T lymphocytes to target cancer cells within the tumor microenvironment. These findings underscore the potential of this adjuvant/antigen-delivering nanovaccine in cancer immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A redox-responsive nanovaccine for cytosolic delivery of antigen and adjuvant to enhance cancer immunotherapy

  • 期刊论文

  • 发表日期：

    2025年5月22日

查看全文
  • Taisheng Liu,
  • Bingkai He,
  • Jiaqing Tao,
  • Shaoying He,
  • Nanlin Fu,
  • Kewei Wang,
  • Hui Fan

摘要

Cancer vaccines have garnered significant attention in cancer immunotherapy because they trigger tumor-specific immune responses. However, their effectiveness is hindered by inefficient antigen and adjuvant delivery at the subcellular level, which is essential to stimulate a robust CD8+ T cell response. This study presents PAR/OVA, a cancer nanovaccine developed by combining imiquimod (R837)-modified polyamidoamine dendrimers with the model protein antigen ovalbumin (OVA). Within the nanovaccine, R837 is an adjuvant for the Toll-like receptor 7 (TLR7) pathway and a structural component that facilitates OVA loading. In dendritic cells (DCs), the high cytoplasmic glutathione levels triggered the breakdown of PAR/OVA, releasing OVA and R837, which induced DC activation and antigen cross-presentation. Furthermore, PAR/OVA vaccination showed a protective effect and effectively inhibited B16-OVA tumor progression, indicating its potential in cancer immunotherapy. Combining this vaccine with an immune checkpoint blockade enhanced antitumor efficacy by improving the ability of cytotoxic T lymphocytes to target cancer cells within the tumor microenvironment. These findings underscore the potential of this adjuvant/antigen-delivering nanovaccine in cancer immunotherapy.